Estimation of polymorphisms in the drug-metabolizing enzyme, cytochrome P450 2C19 gene in six major ethnicities of Pakistan

References

• Scott SA, Sangkuhl K, Shuldiner AR, et al. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genomics. 2012;22(2):159–165.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138:103–141.
   PubMed Web of Science ®Google Scholar
• Hamdy SI, Hiratsuka M, Narahara K, et al. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol. 2002;53(6):596–603.
   PubMed Web of Science ®Google Scholar
• Balabanova L, Golotin V, Podvolotskaya A, et al. Genetically modified proteins: functional improvement and chimeragenesis. Bioengineered. 2015;6(5):262–274.
   PubMed Web of Science ®Google Scholar
• Holmes DR, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American college of cardiology foundation task force on clinical expert consensus documents and the American heart association endorsed by the society for cardiovascular angiography and interventions and the society of thoracic surgeons. J Am Coll Cardiol. 2010;56:321–341.
   PubMed Web of Science ®Google Scholar
• Setiabudy R, Kusaka M, Chiba K, et al. Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4ʹ-hydroxylation recruited from an Indonesian population. Br J Clin Pharmacol. 1995;39(3):297–303.
   PubMed Web of Science ®Google Scholar
• Sa W, Na H, Skjelbo E, et al. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism-a panel study. Br J Clin Pharmacol. 1991;31(6):689–692.
   PubMed Web of Science ®Google Scholar
• de Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994;269(22):15419–15422.
   PubMed Web of Science ®Google Scholar
• De Morais SM, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994;46:594–598.
   PubMed Web of Science ®Google Scholar
• Wang H, An N, Wang H, et al. Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4′-hydroxylation and omeprazole 5′-Hydroxylation. Drug Metab Dispos Biol Fate Chem. 2011;39(5):830–837.
   PubMed Web of Science ®Google Scholar
• Auton A, Abecasis GR, Altshuler DM, et al. A global reference for human genetic variation. Nature. 2015;526:68–74.
   PubMed Web of Science ®Google Scholar
• Block Wise Provisional Summary Results of 6th Population & Housing Census-2017 [ As on January 03, 2018] Pakistan bureau of statistics [internet]. [cited 2020 Feb 11]; Available from: http://www.pbs.gov.pk/content/block-wise-provisional-summary-results-6th-population-housing-census-2017-january-03-2018
   Google Scholar
• Taus-Bolstad S. Pakistan in pictures. Revised, Expanded ed. Minneapolis: Lerner Pub Group; 2003.
   Google Scholar
• Bathum L, Andersen-Ranberg K, Boldsen J, et al. Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevityRole of CYP2D6 and CYP2C19 in longevity. Eur J Clin Pharmacol. 1998;54(5):427–430.
   PubMed Web of Science ®Google Scholar
• Brockmoller J, Rost K, Gross D, et al. Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G–>A-splice site mutation. - abstract - Europe PMC. Pharmacogenetics. 1995;5:80–88.
   PubMedGoogle Scholar
• Dandara C, Masimirembwa CM, Magimba A, et al. Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients. Eur J Clin Pharmacol. 2001;57(1):11–17.
   PubMed Web of Science ®Google Scholar
• Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics. 1997;7(1):59–64.
   PubMedGoogle Scholar
• Herrlin K, Massele AY, Jande M, et al. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther. 1998;64(4):391–401.
   PubMed Web of Science ®Google Scholar
• Hoskins JM, Shenfield GM, Gross AS. Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population. Br J Clin Pharmacol. 1998;46(5):499–504.
   PubMed Web of Science ®Google Scholar
• Persson I, Aklillu E, Rodrigues F, et al. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics. 1996;6(6):521–526.
   PubMedGoogle Scholar
• Ruas JL, Lechner MC. Allele frequency of CYP2C19 in a Portuguese population. Pharmacogenetics. 1997;7(4):333–335.
   PubMedGoogle Scholar
• Rudberg I, Mohebi B, Hermann M, et al. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther. 2008;83(2):322–327.
   PubMed Web of Science ®Google Scholar
• Yamada H, Dahl ML, Lannfelt L, et al. CYP2D6 and CYP2C19 genotypes in an elderly Swedish population. Eur J Clin Pharmacol. 1998;54(6):479–481.
   PubMed Web of Science ®Google Scholar
• Jurima-Romet M, Goldstein JA, LeBelle M, et al. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population. Pharmacogenetics. 1996;6(4):329–339.
   PubMedGoogle Scholar
• Dehbozorgi M, Kamalidehghan B, Hosseini I, et al. Prevalence of the CYP2C19*2 (681 G>A), *3 (636 G>A) and *17 (‑806 C>T) alleles among an Iranian population of different ethnicities. Mol Med Rep. 2018;17:4195–4202.
   PubMed Web of Science ®Google Scholar
• Lamba JK. CYP2C19 genetic mutations in North Indians. Clin Pharmacol Ther. 2000;68(3):328–335.
   PubMed Web of Science ®Google Scholar
• Bhatti S, Aslamkhan M, Attimonelli M, et al. Mitochondrial DNA variation in the Sindh population of Pakistan. 2017;
   Google Scholar
• Bergström A, McCarthy SA, Hui R, et al. Insights into human genetic variation and population history from 929 diverse genomes. Science [Internet] 2020 [cited 2020 Sep 4]; 367. Available from: https://science.sciencemag.org/content/367/6484/eaay5012
   Google Scholar
• Metspalu M, Romero IG, Yunusbayev B, et al. Shared and unique components of human population structure and genome-wide signals of positive selection in South Asia. Am J Hum Genet. 2011;89(6):731–744.
   PubMed Web of Science ®Google Scholar
• Ayub Q, Mansoor A, Ismail M, et al. Reconstruction of human evolutionary tree using polymorphic autosomal microsatellites. Am J Phys Anthropol. 2003;122(3):259–268.
   PubMed Web of Science ®Google Scholar
• Mansoor A, Mazhar K, Khaliq S, et al. Investigation of the Greek ancestry of populations from northern Pakistan. Hum Genet. 2004;114(5):484–490.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Khan G The history of baloch and balochistan: a critical appraisal.: 14.
   Google Scholar
• Riaz S, Mansoor A, Siddiqi S, et al. Association of CYP2C19*2 and *17 genetic variants with hypertension in Pakistani population. Trop J Pharm Res. 2019;18(4):851–855.
   Web of Science ®Google Scholar
• Afsar NA, Bruckmueller H, Werk AN, et al. Implications of genetic variation of common drug metabolizing enzymes and ABC transporters among the Pakistani Population. Sci Rep. 2019;9(1):7323.
   PubMedGoogle Scholar
• Rehman NU, Begum N, Ali L, et al. LIPID PEROXIDATION, ANTIGLYCATION, CYTOTOXIC, PHYTOTOXIC, ANTIOXIDANT, ANTIPLATELET AND ANTIMICROBIAL ACTIVITIES OF AJUGA BRACTEOSA AGAINST VARIOUS PATHOGENS. 2015.
   Google Scholar
• Afsar NA, Haenisch S, Mateen A, et al. Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy. Basic Clin Pharmacol Toxicol. 2010;107(1):570–576.
   PubMed Web of Science ®Google Scholar
• Ahmed S, Altaf N, Ejaz M, et al. Variations in the frequencies of polymorphisms in the CYP2C9 gene in six major ethnicities of Pakistan. Sci Rep. 2020;10(1):19370.
   PubMed Web of Science ®Google Scholar